Tasocitinib Improves Physical Function in Rheumatoid Arthritis
Links shared publicly online about this topic
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Health News - redOrbit
redorbit.com — “NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.” View full resource at redorbit.com
Most Recently Shared on November 7, 2010 at 11:23 pm By:
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Si... http://bit.ly/bHHxot
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010
pfizer.mediaroom.com — “In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010” View full resource at pfizer.mediaroom.com
Most Recently Shared on November 7, 2010 at 10:08 pm By:
Press Release: In First Phase 3 Trial...http://bit.ly/c9aVVz
Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
www-origin2.roche.com — “Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis” View full resource at www-origin2.roche.com
Most Recently Shared on May 26, 2009 at 2:44 pm By:
eyeonfda Pharma and Health Lawyer
2-yr data reinforce effectiveness of ACTEMRA in inhibiting joint damage / improving physical function in patients RA http://twurl.nl/mwxzsh
Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
roche.com — “Roche - Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis” View full resource at roche.com
Most Recently Shared on May 25, 2009 at 5:42 am By:
Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in p.. http://tinyurl.com/q6m527
Actemra gains indication for inhibition and improvement of RA - ONA
oncologynurseadvisor.com — “Genentech announced that the FDA has approved Actemra (tocilizumab injection) for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis (RA), when given in combination with methotrexate (MTX).” View full resource at oncologynurseadvisor.com
Most Recently Shared on January 5, 2011 at 6:06 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Actemra gains indication for inhibition and improvement of RA http://goo.gl/fb/2cR3d
Actemra gains indication for inhibition and improvement of RA - MPR
empr.com — “Genentech announced that the FDA has approved Actemra (tocilizumab injection) for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis (RA), when given in combination with methotrexate (MTX).” View full resource at empr.com
Most Recently Shared on January 5, 2011 at 6:12 pm By:
MPR News: Actemra gains indication for inhibition and improvement of RA: Genentech announced that the FDA has ap... http://bit.ly/ebgisU
Exercise Improves Functional And Psychological Ability And Reduces Steroid Need In Rheumatoid Arthritis
sciencedaily.com — “Undertaking a supervised exercise program can have beneficial effects on functional status and physical function, reduce the need for daily corticosteroid and anti-inflammatory intake and improve levels of depression and anxiety in people with rheumatoid arthritis, according to a new study.” View full resource at sciencedaily.com
Most Recently Shared on June 23, 2009 at 6:07 pm By:
Science Daily: Exercise Improves Functional And Psychological Ability And Reduces: http://tinyurl.com/pltw6v Full http://tinyurl.com/maaoow
New SIMPONI(TM) Data Show Long-Term Efficacy In Treatment Of Rheumatoid Arthritis
medicalnewstoday.com — “New long-term data from two pivotal, phase 3 clinical trials showed that patients with active rheumatoid arthritis (ra) receiving simponi(tm) (golimumab) every four weeks achieved sustained improv” View full resource at medicalnewstoday.com
Most Recently Shared on October 20, 2009 at 11:39 am By:
MNT Arthritis News Health News
New SIMPONI(TM) Data Show Long-Term Efficacy In Treatment Of Rheumatoid Arthritis: New long-term data from two .. http://bit.ly/vu7b7
Medical News: FDA Green Lights New Indication for RA Drug - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA expanded the indication of the rheumatoid arthritis drug tocilizumab (Actemra) to inhibit and slow structural joint damage, improve physical function, and treat severely active r” View full resource at medpagetoday.com
Most Recently Shared on January 6, 2011 at 8:30 pm By:
FDA Green Lights New Indication for RA Drug http://bit.ly/e3aw7x
UPDATE 4-Pfizer arthritis drug meets main goals of trial | Reuters
reuters.com — “* Pfizer's JAK-inhibitor RA drug meets goals of trial * Reduced signs and symptoms of rheumatoid arthritis * Drug improved physical function, disease remission (More analyst comment, updates share” View full resource at reuters.com
Most Recently Shared on March 5, 2011 at 6:40 pm By:
Lisa Richwine Health Communicator
Pfizer JAK-inhibitor arthritis drug meets main goals of trial http://reut.rs/fkMx9j
FDA Grants Supplemental Approval for Actemra (tocilizumab)
drugs.com — “Actemra (tocilizumab) is used to treat rheumatoid arthritis. Includes Actemra side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on January 8, 2011 at 7:10 am By:
Drugs and Devices OW OW Health
FDA Grants Supplemental Approval for Actemra (tocilizumab): SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--... http://bit.ly/hYVEcs #drug
Pfizer arthritis drug succeeds in late stage trial | Reuters
reuters.com — “NEW YORK, Nov 7 Reuters) - A closely watched experimental drug for rheumatoid arthritis being developed by Pfizer Inc significantly reduced symptoms and improved physical function, according to data from” View full resource at reuters.com
Most Recently Shared on November 7, 2010 at 10:47 pm By:
Pfizer arthritis drug succeeds in late stage trial http://dlvr.it/89dxZ
Pfizer arthritis drug succeeds in late stage trial | Reuters
reuters.com — “NEW YORK, Nov 7 Reuters) - A closely watched experimental drug for rheumatoid arthritis being developed by Pfizer Inc significantly reduced symptoms and improved physical function, according to data from” View full resource at reuters.com
Most Recently Shared on November 7, 2010 at 10:55 pm By:
Pfizer arthritis drug succeeds in late stage trial: NEW YORK, Nov 7 Reuters) - A closely watched experimental dr... http://bit.ly/biDdXj
Rheumatology Medical News about Arthritis, Rheumatoid Fatigue Pain
mdlinx.com — “Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol” View full resource at mdlinx.com
Most Recently Shared on June 17, 2010 at 10:29 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Physical function improvements and relief from fatigue and pain are associated with increased product... http://bit.ly/dBj6w2 #Rheumatology
UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis - Drugs.com MedNews
drugs.com — “In adult patients with moderate to severely active rheumatoid arthritis, Cimzia provided rapid and sustained improvements in ACR responses, DAS 28 scores, HAQ-D” View full resource at drugs.com
Most Recently Shared on June 16, 2010 at 8:45 pm By:
UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of jo... http://bit.ly/91qZTL
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Oral Health OW
Organizing oral health resources shared by health experts, advocates, and organizations into WisdomCards.
-
Pfizer Inc.
The official site for Pfizer Inc., where we apply science and our global resources to improve health and well-being at every stage of life. I'm Jen Kokell, GMR
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
Advertisement
